Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimitri P Mikhailidis

Showing results (131-140 of 923) with videos related to

Pageof 93
Sort By:
Current Vascular Pharmacology|November 4, 2010
Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 yearsEirini Lioudaki, Emmanuel S Ganotakis, Dimitri P Mikhailidis
Current Opinion in Cardiology|February 15, 2023
Are serum uric acid levels predictors of cardiovascular risk? An updateMichael Georgoulis, Dimitri P Mikhailidis, Demosthenes B Panagiotakos
Current Pharmaceutical Design|January 17, 2017
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk ManagementNiki Katsiki, Dimitri P Mikhailidis, Michael J Theodorakis
Journal of Diabetes and Its Complications|January 17, 2017
Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugsNiki Katsiki, Vasilios G Athyros, Dimitri P Mikhailidis
Metabolism: Clinical and Experimental|November 16, 2016
Response letter: Statins and non-alcoholic steatohepatitisVasilios G Athyros, Niki Katsiki, Dimitri P Mikhailidis
Current Pharmaceutical Design|December 4, 2020
Endocrine Disease as a Cause of Cardiovascular Disease: Current PerspectivesPanagiotis Anagnostis, Dimitrios G Goulis, Dimitri P Mikhailidis
Current Pharmaceutical Design|January 5, 2021
Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular DiseaseNiki Katsiki, George D Dimitriadis, Dimitri P Mikhailidis
Current Opinion in Cardiology|April 18, 2013
Epicardial fat and vascular risk: a narrative reviewNiki Katsiki, Dimitri P Mikhailidis, Anthony S Wierzbicki
Cardiovascular Drugs and Therapy|May 29, 2014
The effects of anti-diabetic drugs on LDL subclasses: any role for colesevelam?Manfredi Rizzo, Dimitri P Mikhailidis, Khalid Al-Rasadi
Journal of Cardiovascular Pharmacology and Therapeutics|April 12, 2021
Can We Decrease Epicardial and Pericardial Fat in Patients With Diabetes?Emir M Muzurović, Snežana Vujošević, Dimitri P Mikhailidis
Pageof 93

Showing results (131-140 of 923) with videos related to

Sort By:
Pageof 93
Current Vascular Pharmacology|November 4, 2010
Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 yearsEirini Lioudaki, Emmanuel S Ganotakis, Dimitri P Mikhailidis
Current Opinion in Cardiology|February 15, 2023
Are serum uric acid levels predictors of cardiovascular risk? An updateMichael Georgoulis, Dimitri P Mikhailidis, Demosthenes B Panagiotakos
Current Pharmaceutical Design|January 17, 2017
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk ManagementNiki Katsiki, Dimitri P Mikhailidis, Michael J Theodorakis
Journal of Diabetes and Its Complications|January 17, 2017
Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugsNiki Katsiki, Vasilios G Athyros, Dimitri P Mikhailidis
Metabolism: Clinical and Experimental|November 16, 2016
Response letter: Statins and non-alcoholic steatohepatitisVasilios G Athyros, Niki Katsiki, Dimitri P Mikhailidis
Current Pharmaceutical Design|December 4, 2020
Endocrine Disease as a Cause of Cardiovascular Disease: Current PerspectivesPanagiotis Anagnostis, Dimitrios G Goulis, Dimitri P Mikhailidis
Current Pharmaceutical Design|January 5, 2021
Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular DiseaseNiki Katsiki, George D Dimitriadis, Dimitri P Mikhailidis
Current Opinion in Cardiology|April 18, 2013
Epicardial fat and vascular risk: a narrative reviewNiki Katsiki, Dimitri P Mikhailidis, Anthony S Wierzbicki
Cardiovascular Drugs and Therapy|May 29, 2014
The effects of anti-diabetic drugs on LDL subclasses: any role for colesevelam?Manfredi Rizzo, Dimitri P Mikhailidis, Khalid Al-Rasadi
Journal of Cardiovascular Pharmacology and Therapeutics|April 12, 2021
Can We Decrease Epicardial and Pericardial Fat in Patients With Diabetes?Emir M Muzurović, Snežana Vujošević, Dimitri P Mikhailidis
Pageof 93